43 results
8-K
EX-99.1
PRPO
Precipio Inc
13 Jun 22
Regulation FD Disclosure
5:09pm
laboratory Develop & test new technologies clinically and operationally in the lab Product commercializati on R&D Product Product Product Commercialization … biopsy rejection rate $0.5B Annually In process – expected completion Q1-2023 Product 3: QNS Product description TAM Development Status R&D Product
424B5
rc65oekn1152ph
2 Apr 21
Prospectus supplement for primary offering
2:00pm
8-K
EX-99.1
pui71m
16 Oct 18
Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues
4:41pm
8-K
EX-10.1
6opzfmaowm
9 Aug 18
Precipio Appoints New Board Member to Replace Departing Director
4:31pm
8-K
mkpdco
9 Aug 18
Precipio Appoints New Board Member to Replace Departing Director
4:31pm
8-K
EX-99.1
l7rwndpx72p izx3
21 Nov 17
Precipio Announces Third Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
0177imb 9np7jyjp
14 Nov 17
Precipio Appoints Samuel D. Riccitelli as Chairman of the Board of Directors and Elects David Cohen as Director
12:00am
8-K
EX-99.1
1rxqmpk 4b
13 Nov 17
Precipio, Inc. Announces Closing of $2,748,000 Registered Direct Offering
12:00am